CNS Pharmaceuticals, Inc.
corporate_fare Company Profile
CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 17 items for CNSP at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-16, rated 8/10. Across its 17 most recent items scored 7 or higher, the top rating is 9/10, with 12 rated 8 or above. Recent SEC coverage for CNSP spans 10-Q, 8-K, 424B3, 4.
Recent high-impact activity:
- CNS Pharmaceuticals Q3 2026: $10.0M Nine-Month Loss, $17.2M Cash, Material Weakness Persists
- CNS Pharma Posts $2.6M Q2 Loss, $20M Cash After $22.5M Placement
- CNS Pharma Posts Q2 Loss, Flags Material Weaknesses, and Outlines $22.5M Private Placement
- CNS Pharmaceuticals Details Strategic Pivot and Fully Diluted Capital Structure in Investor Presentation
- CNS Pharmaceuticals Registers 9.8M Shares for Resale, Enabling Massive Dilution from Recent Private Placement
Financial Snapshot
Short Interest & Short Volume
1.00 days to coverFINRA reported short interest of 1,638 shares in CNSP as of the October 30, 2026 settlement, a 26.0% increase from the prior period — about 1.0 days to cover at its recent average daily volume. On November 20, 2026, 22.2% of CNSP volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Moderate riskFiling-implied dilution signals for CNSP, detected from its recent SEC filings · based on capital-structure filings through 2026-05-26.
Resale of 9.8 Million Shares Enabled · Massive Potential Dilution
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →